Ticker brief
ANL ADLAI NORTYE GROUP LTD
Consumer, Non-cyclical · Biotechnology
last close
$15.53
1 day
-1.9%
14 days
+2.1%
mkt cap
·
signals 14d
7
authors 14d
7
crowd 14d
+0.4σ
Sentiment — last 14 days
· daily mean sentiment, 2026-10-15 → 2026-10-15 · now +0.36 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BioStocks | C | -1.77 | 1 | +0.40 |
| @PersimmonTI | A | +0.79 | 1 | +0.20 |
| @CHItrader | B | -0.22 | 1 | +0.40 |
| @OpenOutcrier | C | · | 1 | +0.50 |
| @OzmosiHealth | C | · | 1 | +0.30 |
| @BiopharmIQ | B | · | 1 | +0.25 |
| @PrismMarketView | C | · | 1 | +0.45 |
Recent signals7of 7 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @PrismMarketView | +0.45 | Adlai Nortye signed trial collaboration and drug-supply agreements with Lilly and Merck KGaA. | — | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.25 | The post lists major opening biotech gains and the news associated with each move. | — | tweet ↗ |
| 2026-10-15 | @OzmosiHealth | +0.30 | Adlai Nortye entered a clinical collaboration with Lilly and Merck KGaA to evaluate a drug combination. | — | tweet ↗ |
| 2026-10-15 | @OpenOutcrier | +0.50 | Adlai Nortye announced a global clinical collaboration with Lilly and Merck. | — | tweet ↗ |
| 2026-10-15 | @CHItrader | +0.40 | ANL signs Erbitux clinical-trial supply agreements with Lilly and Merck KGaA. | — | tweet ↗ |
| 2026-10-15 | @PersimmonTI | +0.20 | Expresses interest in an ANL-Lilly biotech development without details. | — | tweet ↗ |
| 2026-10-15 | @BioStocks | +0.40 | ANL entered a clinical collaboration with Lilly and Merck KGaA to test AN4035 plus cetuximab. | — | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.